SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is at the center of investor discussions after its recent Investor Day and Q4 earnings report, with excitement over potential mid-size EV models and an Uber robotaxi partnership clashing with ongoing concerns about substantial cash burn, future capital needs, and a notable short interest.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following an earnings beat, first GAAP profitability, and a new $500M buyback, though its modest forward growth guidance has led to a notable sell-off. Community discussions are sharply divided between conviction in its strong fundamentals and Agentic AI potential, and concerns over growth acceleration and management's communication.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is gaining significant attention due to its new development agreement with Tower Semiconductor to integrate its advanced electro-optic polymer modulators, sparking community excitement that this collaboration is a critical step towards commercialization for high-speed, low-power optical interconnects crucial for AI datacenters, with many speculating on broader industry adoption including NVIDIA.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending as a major partnership with Palantir and World View to develop AI-enabled multi-domain defense systems positions it as a key player, fueling intense debate between those anticipating a monumental short squeeze and others frustrated by ongoing dilution and perceived manipulation suppressing its stock performance.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending following reports of a new wiring flaw causing 737 MAX delivery delays, which adds to ongoing quality control concerns and fuels investor frustration. This comes as the market also debates the potential for a massive aircraft order from China and the dual impact of geopolitical tensions on both commercial aviation demand and increased defense spending.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending due to a recent research report positioning it as a "stealth supplier" for NVIDIA's AI optics revolution through TSMC's COUPE platform, igniting robust community discussion. Investors are keenly debating if this accelerated adoption of Co-Packaged Optics and potential ties to AR glasses will finally drive substantial growth, despite some skepticism regarding prior management promises.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Geopolitical tensions surrounding the Iran conflict and spiking oil prices are driving significant discussion around SPY, with traders actively debating whether the current volatility signals a deeper market downturn or a 'V-shaped' recovery supported by dip buying.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently a focal point for investors following multiple high-profile partnerships, including a collaboration with NVIDIA on a Sovereign AI OS and expanded defense sector engagements. The community is buzzing about the company's accelerating role in AI-driven intelligence and military applications amid rising geopolitical tensions, while also actively debating its valuation and short-term price action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in conversation as the community anticipates significant news and potential partnerships at the upcoming OFC Conference, where the company is set to demonstrate its advanced optical engines and external light sources for AI applications. Many are highlighting POET's competitive photonics technology as a crucial solution for high-speed, power-efficient data interconnects, drawing comparisons to recent momentum in other photonics stocks.

Roma Green Finance Ltd. is a holding company, which engages in the provision of environmental, social and governance, sustainability, and climate change related advisory services through its subsidiaries. Its services include corporate and risk advisory, sustainability strategy services, climate risk advisory, ESG reporting services, and sustainable finance. The company was founded in 2018 and is headquartered in Hong Kong.

Roma Green Finance Ltd - Ordinary Shares - Class A

Roma Green Finance Ltd

Roma Green Finance Ltd is currently trending due to extreme price volatility, marked by multiple trading halts, and community speculation surrounding a recent $1B shelf offering, driving intense debate about its "pump and dump" dynamics and potential for further surges as a low-float Chinese microcap facing NASDAQ compliance scrutiny.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The unit is selling the voucher for $205 million, the company said.&nbsp;</li><li>20% of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.&nbsp;</li><li>The voucher was issued upon approval of ZYCUBO last month for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients.</li></ul>Shares of Fortress Biotech, Inc. (FBIO) rose 10% on Monday after the company announced that its majority-owned unit will sell its voucher for expedited review of a drug application by the U.S. Food and Drug Administration (FDA) for $205 million.Fortress <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html">said</a> that its unit Cyprium Therapeutics, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics, Inc, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited.Twenty percent of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the company said, while also noting that the transaction is subject to customary closing conditions.The PRV program aims to incentivize drug development for rare pediatric diseases.<h2 class="st-heading-2">Cyprium, Sentynl History</h2>Sentynl took over responsibility for the development and commercialization of the drug ZYCUBO from Cyprium in December 2023. Zycubo was approved by the FDA in January for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients. The voucher was issued upon approval of ZYCUBO.Fortress said on Monday that it remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl.“With the PRV sale and three FDA approvals received in the last 15 months for Emrosi, UNLOXCYT, and ZYCUBO, in addition to the recent sale of our former subsidiary Checkpoint Therapeutics to Sun Pharma, we believe that we are well positioned to continue to execute on our portfolio,” said Fortress CEO Lindsay A. Rosenwald.<h2 class="st-heading-2">Cyprium’s Pipeline</h2>Menkes disease is a rare genetic disorder leading to impaired copper transport throughout the body. It causes low copper levels in the brain, resulting in rapid neurodegeneration, seizures, and more. Cyprium is also developing a gene therapy to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with ZYCUBO. The gene therapy is currently in pre-clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FBIO shares jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed optimism for the gene therapy trial data sending the stock skyrocketing. In the short term, the user expects the company to be buoyed by royalties from its Menkes drug, and in the long term, from the gene therapy.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/645614222</stembedurl><a href="https://stocktwits.com/symbol/FBIO">FBIO stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gossamer-bio-stock-plummeted-today-what-is-behind-the-crash/cZRtwTVR4ym">Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

CI's Q4 adjusted EPS beats estimates as Evernorth growth and higher specialty volumes offset fewer medical customers and elevated costs.

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Time to Sell...

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.11	--	--	N/A
Q3 '25	-$0.42	$0.11	126.19%	BEAT
Q2 '25	-$0.36	$0.45	225.00%	BEAT
Q1 '25	-$0.50	-$0.48	3.03%	BEAT
Q4 '24	-$0.75	-$0.17	77.43%	BEAT

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest FBIO News

FBIOFortress Biotech Inc